Granaticin B Form A Crystalline Polymorph Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The current process for producing granaticin B is inefficient, involving multiple steps and leading to undesirable yields and product degradation, necessitating a more feasible large-scale production method.
Innovation Solution
A stable crystalline polymorph of granaticin B, named Form A, is discovered and characterized through techniques like x-ray powder diffraction and differential scanning calorimetry, which can be prepared via evaporative crystallization from chloroform/methanol or methanol/acetone, enabling large-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional fermentation and purification process is used, then granaticin B can be obtained, but the yield is low and product degradation occurs
Solution Approach 1:
The patent applies parameter changes by optimizing fermentation conditions including pH (adjusted to 2.0-3.0 with HCl), temperature (25-30°C), and incubation time (72-96 hours) to maximize granaticin B production and stability, thereby improving yield and preventing degradation
Solution Approach 2:
The patent utilizes phase transitions through extraction processes where granaticin B is transferred from aqueous fermentation broth to organic solvents (ethyl acetate, n-butanol), and subsequently purified through chromatography and crystallization phases to enhance yield and product integrity
2Manufacturing precision
If multiple purification steps are used, then granaticin B can be isolated, but the process complexity increases
Solution Approach 1:
The patent segments the purification process into distinct stages: filtration to remove mycelium, extraction with organic solvents, and chromatography purification. This segmentation allows each step to be optimized independently while maintaining overall process manageability and effectiveness
Solution Approach 2:
The patent uses intermediary substances including organic solvents (ethyl acetate, n-butanol) for extraction and silica gel or C18 reverse phase resin for chromatography as intermediate media to facilitate the separation and purification of granaticin B from fermentation broth
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Form A provides improved stability and solubility, reducing degradation and facilitating large-scale production, making it suitable for clinical and research applications in treating bacterial infections and proliferative diseases.
Implementation Method 1
the methods involve evaporative crystallization from chloroform/methanol or methanol/acetone
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a crystalline Form A of Compound 1, also referred to as Granaticin B, and pharmaceutically compositions thereof. The present invention also provides methods of treating a microbial infection, or a disease, disorder, or condition associated with abnormal cellular proliferation, using crystalline Form A of Compound 1 or pharmaceutical compositions thereof.